⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26999332 | 1.00 | — | — | |
| SCHEMBL27393348 | 1.00 | — | — | |
| SCHEMBL9810391 | 1.00 | — | — | |
| SCHEMBL15771500 | 1.00 | — | — | |
| SCHEMBL3332078 | 1.00 | — | — | |
| SCHEMBL3332068 | 1.00 | — | — | |
| SCHEMBL3332075 | 1.00 | — | — | |
| SCHEMBL75491 | 1.00 | — | — | |
| SCHEMBL19604523 | 1.00 | — | — | |
| SCHEMBL5865801 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3812379-A1 | CRYSTALLINE FORM OF A N-(PYRAZOL-4-YL)SULFONYL-6-(PYRAZOL-1-YL)-2-(PYRROLIDIN-1-YL)PYRIDINE-3-CARBOXAMIDE FOR TREATING CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210047295-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| EP-3551622-B1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10793547-B2 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2018107100-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2018-06-14 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2902030-B1 | Thienotriazolodiazepine compounds for treating neoplasia | DANA FARBER CANCER INST INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-7056925-B2 | for example, N-{2-[benzyl(2-hydroxyethyl)amino]-5-bromophenyl)}-N'-(5-cyano-2-pyrazinyl)urea, N-{5-bromo-2-[(2-hydroxy-2-phenylethyl)(methyl)amino]phenyl}-N'-(5-cyano-2-pyrazinyl)urea; anticarcinogenic agents | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040259885-A1 | Urea kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040034038-A1 | Urea kinase inhibitors | ABBOTT LABORATORIES | 2004-02-19 | — | — | US | disclosed |